Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Go back to Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 5.70 +0.04 (0.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.66 | 52 Week High | $45.34 | |||
| Open | $5.60 | 52 Week Low | $15.92 | |||
| Day High | $5.82 | P/E | 2.45 | |||
| Day Low | $5.60 | EPS | $2.33 | |||
| Volume | 679,238 | |||||
